Aurobindo Pharma Limited is a vertically integrated pharmaceutical company that manufactures and markets generic pharmaceuticals and active pharmaceutical ingredients (APIs). Headquartered in Hyderabad, India, Aurobindo Pharma has a strong global presence, exporting to over 150 countries. The company focuses on producing high-quality, affordable medicines across various therapeutic areas, including anti-retrovirals, cardiovascular, central nervous system, gastroenterologicals, and anti-biotics. Aurobindo is committed to research and development, with multiple advanced R&D centers and a robust pipeline of products.
The headquarters serves as the central hub for Aurobindo Pharma's global operations, including strategic planning, corporate governance, research and development oversight, financial management, and international business development.
The corporate office is situated in Hitech City, a modern business district, reflecting the company's scale and technological focus. It houses key administrative and strategic functions.
Aurobindo Pharma fosters a work environment centered on innovation, quality, integrity, and customer satisfaction. There is an emphasis on continuous learning, collaboration, and contributing to global healthcare affordability.
The Hyderabad headquarters is strategically vital, anchoring Aurobindo's extensive global manufacturing and marketing network. It's the command center for operations spanning over 150 countries and multiple advanced R&D and manufacturing facilities.
Aurobindo Pharma maintains a robust global presence across more than 150 countries. Key functions supported globally include: Research & Development (multiple centers), manufacturing of Active Pharmaceutical Ingredients (APIs) and Finished Dosage Forms (FDF), quality assurance and control, regulatory affairs for diverse international markets, global supply chain management, and marketing and sales operations tailored to regional needs.
Water Mark Building, Plot No. 11, Survey No. 9, Kondapur, Hitech City
Hyderabad
Telangana
India
Address: 279 Princeton Hightstown Rd, East Windsor, NJ 08520, USA
To spearhead Aurobindo's growth and market penetration in the United States, ensuring compliance with FDA standards and efficient delivery of affordable medicines to American consumers.
Address: Vault 14, Level 2, Valletta Waterfront, Floriana, FRN 1913, Malta
To facilitate market access, regulatory compliance (EMA), and business development within the European Union and other European markets, ensuring a strong presence in the region.
Address: Unit 01-02, 26F, Yongda International Tower, No. 2277 Longyang Road, Pudong New Area, Shanghai, China
To leverage China's capabilities in API manufacturing and intermediates, as well as to explore market opportunities within China's growing pharmaceutical sector.
Highperformr Signals uncover buying intent and give you clear insights to target the right accounts at the right time — helping your sales, marketing, and GTM teams close more deals, faster.
As of April 2025, AUROBINDO PHARMA LTD' leadership includes:
AUROBINDO PHARMA LTD has been backed by several prominent investors over the years, including:
Aurobindo Pharma has focused on strategic appointments and ensuring leadership continuity in the past 12-18 months. Key movements include strengthening the finance leadership and re-confirming experienced directors on the board. Publicly announced C-suite departures have been minimal.
Discover the tools AUROBINDO PHARMA LTD uses. Highperformr reveals the technologies powering your target accounts — helping your sales, marketing, and GTM teams prioritize smarter and close faster.
Aurobindo Pharma commonly uses standardized email formats for its employees. While specific patterns can vary by department or region, a frequently observed format is combining the employee's first initial and last name with the company domain.
[firstinitial][lastname]@aurobindo.com
Format
jsmith@aurobindo.com
Example
75%
Success rate
The Economic Times • March 5, 2024
Eugia Pharma Specialities Ltd., a wholly owned subsidiary of Aurobindo Pharma, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Letrozole Tablets USP, 2.5 mg. These tablets are indicated for treating certain types of breast cancer in postmenopausal women....more
The Hindu BusinessLine • February 28, 2024
CuraTeQ Biologics, a subsidiary of Aurobindo Pharma focused on biosimilars, announced plans to invest approximately ₹300 crore to establish a new biologics manufacturing facility in Hyderabad. This investment aims to expand its production capabilities and strengthen its position in the biosimilar market....more
Moneycontrol • February 22, 2024
Aurobindo Pharma has received final approval from the USFDA for its Plerixafor Injection, 24 mg/1.2 mL (20 mg/mL), in single-dose vials. This product is bioequivalent and therapeutically equivalent to the reference listed drug Mozobil (plerixafor) injection and is used in the treatment of certain cancers....more
See where a company’s workforce is located, by country or region.
View past and recent funding rounds with amounts and investors.
Understand company revenue estimates and financial scale.
Track active roles and hiring trends to spot growth signals.
Discover what a company offers—products, platforms, and solutions.
Get the company’s official SIC and NAICS classifications.
Analyze visitor volume, engagement, and top traffic sources.
Explore LinkedIn, Twitter, and other active social profiles.
Identify top competitors based on similar business traits.
Explore companies in depth — from the tech they use to recent funding, hiring trends, and buyer signals — all in one powerful view.
Highperformr AI helps you surface the right accounts and enrich your CRM with verified company and contact insights, so your teams can prioritize and engage faster.
Thousands of companies, including AUROBINDO PHARMA LTD, are just a search away.